MORE►
BARDA
TFF Pharmaceuticals CEO Dr. Harlan Weisman [Photo TFF, Background DI Studio]
Fort Worth’s TFF Pharmaceuticals Partners to Develop Dry Powder-Inhaled mRNA Treatment for Flu and COVID
by David Seeley | Sep 13, 2024
Respiratory illnesses like influenza and COVID can change rapidly, requiring the nimble development and delivery of antiviral drugs to combat them. TFF is now partnering with Atlanta's Emory University and the Biomedical Advanced Research and Development Authority (BARDA) to test the feasibility of converting an Emory-developed mRNA antiviral into a dry powder formulation that needs no cold-chain storage.
by David Seeley |
Sep 28, 2023
The contract is for the advanced development of Spectral MD's DeepView System, an AI-driven burn wound imaging device designed to be used at emergency departments, trauma centers, and burn centers.
MORE►
by Lance Murray |
Jul 24, 2019
Spectral's device uses real-time data and artificial intelligence to help look beneath the skin's surface and assess wound and burn damage, which can help doctors improve treatments and outcomes — as well as be a tool in the response to mass burn casualties in a national emergency.
MORE►
